Will Radiopharmaceutical Company AAA Be M&A Fodder For Novartis?
Executive Summary
Novartis, which is focused on securing bolt-on acquisitions rather than mega-M&A to bolster its pipeline, might have found the right target in French radiopharmaceutical company Advanced Accelerator Applications – if rumors are to be believed.
You may also be interested in...
Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Biopharma Quarterly Deal-making Statistics, Q4 2017
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.
Will AAA's Nuclear Med Offerings Turn M&A Buzz Into A Deal?
Advanced Accelerator Applications (AAA) has hit the headlines with recent rumors of a potential acquisition deal from Novartis. Now that the radiopharmaceutical company has its first therapeutic product approved and ready for commercialization, is AAA really ready to sign the dotted line?